Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 109
Filtrar
1.
ACS Infect Dis ; 10(5): 1612-1623, 2024 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-38597503

RESUMO

Fusobacterium nucleatum, a pathobiont inhabiting the oral cavity, contributes to opportunistic diseases, such as periodontal diseases and gastrointestinal cancers, which involve microbiota imbalance. Broad-spectrum antimicrobial agents, while effective against F. nucleatum infections, can exacerbate dysbiosis. This necessitates the discovery of more targeted narrow-spectrum antimicrobial agents. We therefore investigated the potential for the fusobacterial enoyl-ACP reductase II (ENR II) isoenzyme FnFabK (C4N14_ 04250) as a narrow-spectrum drug target. ENRs catalyze the rate-limiting step in the bacterial fatty acid synthesis pathway. Bioinformatics revealed that of the four distinct bacterial ENR isoforms, F. nucleatum specifically encodes FnFabK. Genetic studies revealed that fabK was indispensable for F. nucleatum growth, as the gene could not be deleted, and silencing of its mRNA inhibited growth under the test conditions. Remarkably, exogenous fatty acids failed to rescue growth inhibition caused by the silencing of fabK. Screening of synthetic phenylimidazole analogues of a known FabK inhibitor identified an inhibitor (i.e., 681) of FnFabK enzymatic activity and F. nucleatum growth, with an IC50 of 2.1 µM (1.0 µg/mL) and a MIC of 0.4 µg/mL, respectively. Exogenous fatty acids did not attenuate the activity of 681 against F. nucleatum. Furthermore, FnFabK was confirmed as the intracellular target of 681 based on the overexpression of FnFabK shifting MICs and 681-resistant mutants having amino acid substitutions in FnFabK or mutations in other genetic loci affecting fatty acid biosynthesis. 681 had minimal activity against a range of commensal flora, and it was less active against streptococci in physiologic fatty acids. Taken together, FnFabK is an essential enzyme that is amenable to drug targeting for the discovery and development of narrow-spectrum antimicrobial agents.


Assuntos
Antibacterianos , Fusobacterium nucleatum , Fusobacterium nucleatum/enzimologia , Fusobacterium nucleatum/efeitos dos fármacos , Fusobacterium nucleatum/genética , Antibacterianos/farmacologia , Antibacterianos/química , Humanos , Enoil-(Proteína de Transporte de Acila) Redutase (NADH)/genética , Enoil-(Proteína de Transporte de Acila) Redutase (NADH)/antagonistas & inibidores , Enoil-(Proteína de Transporte de Acila) Redutase (NADH)/metabolismo , Testes de Sensibilidade Microbiana , Proteínas de Bactérias/genética , Proteínas de Bactérias/metabolismo , Proteínas de Bactérias/antagonistas & inibidores , Ácidos Graxos/química , Infecções por Fusobacterium/microbiologia , Infecções por Fusobacterium/tratamento farmacológico , Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/química
2.
Free Radic Biol Med ; 220: 125-138, 2024 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-38657754

RESUMO

Fusobacterium (F.) nucleatum is a carcinogenesis microbiota in colorectal cancer (CRC). Growing evidence shows that F. nucleatum contributes to chemoresistance. Ferroptosis is reported to restore the susceptibility of resistant cells to chemotherapy. However, the role of gut microbiota affecting ferroptosis in chemoresistance remains unclear. Here, we examined the CRC tissues of patients using 16S rRNA sequencing to investigate the possible connection between gut microbiota dysbiosis and the relapse of CRC. We found that a high abundance of F. nucleatum in CRC tissue is associated with relapse. We further demonstrated that F. nucleatum induced oxaliplatin resistance in vitro and in vivo. The transcriptome of an F. nucleatum-infected cell revealed ferroptosis was associated with F. nucleatum infection. We perform malondialdehyde, ferrous iron, and glutathione assays to verify the effect of F. nucleatum on ferroptosis under oxaliplatin treatment in vivo and in vitro. Mechanistically, F. nucleatum promoted oxaliplatin resistance by overexpressing GPX4 and then inhibiting ferroptosis. E-cadherin/ß-catenin/TCF4 pathway conducted the GPX4 overexpression effect of F. nucleatum. The chromatin immuno-precipitation quantitative PCR (CHIP-qPCR) and dual-luciferase reporter assay showed that F. nucleatum promoted TCF4 binding with GPX4. We also determined the E-cadherin/ß-catenin/TCF4/GPX4 axis related to tumor tissue F. nucleatum status and CRC relapse clinically. Here, we revealed the contribution of F. nucleatum to oxaliplatin resistance by inhibiting ferroptosis in CRC. Targeting F. nucleatum and ferroptosis will provide valuable insight into chemoresistance management and may improve outcomes for patients with CRC.


Assuntos
Caderinas , Neoplasias Colorretais , Resistencia a Medicamentos Antineoplásicos , Ferroptose , Fusobacterium nucleatum , Microbioma Gastrointestinal , Oxaliplatina , Fosfolipídeo Hidroperóxido Glutationa Peroxidase , beta Catenina , Ferroptose/efeitos dos fármacos , Ferroptose/genética , Humanos , Neoplasias Colorretais/patologia , Neoplasias Colorretais/microbiologia , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/metabolismo , Neoplasias Colorretais/genética , Caderinas/metabolismo , Caderinas/genética , Oxaliplatina/farmacologia , beta Catenina/metabolismo , beta Catenina/genética , Fosfolipídeo Hidroperóxido Glutationa Peroxidase/metabolismo , Fosfolipídeo Hidroperóxido Glutationa Peroxidase/genética , Animais , Fusobacterium nucleatum/patogenicidade , Camundongos , Microbioma Gastrointestinal/efeitos dos fármacos , Ensaios Antitumorais Modelo de Xenoenxerto , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Masculino , Antígenos CD/metabolismo , Antígenos CD/genética , Feminino , Linhagem Celular Tumoral , Infecções por Fusobacterium/microbiologia , Infecções por Fusobacterium/tratamento farmacológico , Infecções por Fusobacterium/metabolismo , Infecções por Fusobacterium/genética , Infecções por Fusobacterium/patologia , Disbiose/microbiologia , Fator de Transcrição 4/metabolismo , Fator de Transcrição 4/genética , Camundongos Nus
3.
Medicina (Kaunas) ; 60(2)2024 Jan 31.
Artigo em Inglês | MEDLINE | ID: mdl-38399536

RESUMO

Background and Objectives: Anaerobic bacteria like Fusobacterium can lead to severe and life-threatening infections. The inherent complexities in the isolation of these bacteria may result in diagnostic and therapeutic delays, thereby escalating both morbidity and mortality rates. We aimed to examine data from patients with infections due to Fusobacterium to gain insights into the epidemiology and clinical outcomes of patients with these infections. Methods and Results: We conducted a retrospective analysis of clinical data from a cohort of patients with cultures positive for Fusobacterium species at a tertiary care medical center in the United States. Between 2009 and 2015, we identified 96 patients with cultures positive for Fusobacterium. Patients could be categorized into three groups based on the site of primary infection. Patients with head and neck infections constituted 37% (n 36). Patients with infections of other soft tissue sites accounted for 38.5% (n 37). Patients with anaerobic bacteremia due to Fusobacterium formed 24% (n 23) of the cohort. Surgical intervention coupled with antibiotic therapy emerged as cornerstones of management for patients with head and neck or other soft tissue infections, who generally exhibited more favorable outcomes. Patients with bacteremia were older, more likely to have malignancy, and had a high mortality rate. When speciation was available, Fusobacterium necrophorum was the most frequently isolated species. Conclusions: Our retrospective analysis of epidemiology and clinical outcomes of Fusobacterium infections revealed three distinct cohorts. Patients with head, neck, or soft tissue infections had better outcomes than those with bacteremia. Our findings highlight the importance of employing management strategies based on infection site and underlying comorbidities in patients with Fusobacterium infections. Further research is needed to investigate the optimal therapeutic strategies and identify prognostic indicators to improve clinical outcomes for these complex infections.


Assuntos
Bacteriemia , Infecções por Fusobacterium , Infecções dos Tecidos Moles , Humanos , Estudos Retrospectivos , Infecções por Fusobacterium/tratamento farmacológico , Infecções por Fusobacterium/epidemiologia , Infecções por Fusobacterium/diagnóstico , Fusobacterium , Bacteriemia/tratamento farmacológico , Bacteriemia/epidemiologia
4.
Infect Disord Drug Targets ; 24(4): 53-57, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38178665

RESUMO

Background: Infections caused by anaerobic bacteria occur frequently and can be serious and life-threatening. Anaerobes are a rare cause of community-acquired pneumonia with Streptococcus pneumonia and respiratory viruses being the most frequently detected pathogens. We, herein, report a case of Fusobacterium/Peptostreptococcus parapneumonic effusion with empyema in a patient without risk factors for aspiration pneumonia. This case presents an opportunity to discuss an unusual case of community-acquired empyema secondary to anaerobic infection in a patient without the common risk factors for aspiration.

Case Presentation: A 59-year-old male patient without significant past medical history apart from a twenty-five-year history of smoking presented due to left flank pain and shortness of breath. Findings of a complicated parapneumonic effusion were found on imaging, resulting in surgical decortication and prolonged antibiotic therapy.

Discussion: Parapneumonic effusions and empyema are relatively common complications of pneumonia. It is important to note that the incidence of anaerobic empyema has been on the rise due to more modern culturing techniques.

Conclusion: This case highlights an unusual presentation of community-acquired empyema secondary to anaerobes without any risk factors for aspiration pneumonia. Therefore, clinicians should consider the possibility of anaerobic coverage in the treatment of community-acquired empyema in the appropriate setting.

.


Assuntos
Antibacterianos , Infecções Comunitárias Adquiridas , Fusobacterium , Peptostreptococcus , Humanos , Masculino , Pessoa de Meia-Idade , Antibacterianos/uso terapêutico , Infecções Comunitárias Adquiridas/microbiologia , Infecções Comunitárias Adquiridas/tratamento farmacológico , Peptostreptococcus/isolamento & purificação , Fusobacterium/isolamento & purificação , Empiema Pleural/microbiologia , Empiema Pleural/tratamento farmacológico , Empiema/microbiologia , Infecções por Fusobacterium/tratamento farmacológico , Infecções por Fusobacterium/microbiologia , Infecções por Fusobacterium/complicações , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Infecções por Bactérias Gram-Positivas/microbiologia
5.
Immun Inflamm Dis ; 11(11): e1067, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-38018574

RESUMO

OBJECTIVE: Colorectal cancer (CRC) represents a leading cause of cancer-related deaths. Metronidazole (MNZ) is exceedingly implicated in CRC. This study explored the roles of MNZ in mouse CRC occurrence and liver metastasis (CRLM). METHODS: Male BALB/c nude mice were subjected to CRC and CRLM modeling, orally administration with MNZ (1 g/L) 1 week before modeling, and disease activity index (DAI) evaluation. Fresh stool and anal swab samples were collected on the morning of the 28th day after modeling. The relative expression of Fusobacterium nucleatum (F. nucleatum) DNA was assessed by quantitative polymerase chain reaction. After euthanasia, tumor tissues and liver tissues were separated and the tumor volume and weight change were measured. The liver tissues were stained with hematoxylin-eosin to quantitatively analyze the metastatic liver nodules. Malignant tumor biomarker Ki67 protein levels in liver tissues/DNA from stool samples were detected by immunohistochemistry/high-throughput 16S rRNA gene sequencing. Bioinformatics analysis was performed on the raw sequence data to analyze microbial community richness (Chao1 index, ACE index) and microbial community diversity (Shannon index). RESULTS: The DAI and F. nucleatum DNA relative expression in feces and anal swabs of the CRC and CRLM groups were raised and repressed after MNZ intervention. MNZ repressed tumor occurrence and growth in mice to a certain extent, alleviated CRLM malignant degree (reduced liver metastases and Ki67-positive cell density/number), and suppressed CRC liver metastasis by regulating intestinal flora structure, which affected the intestinal characteristic flora of CRC and CRLM mice. CONCLUSION: MNZ suppressed CRC occurrence and CRLM in mice by regulating intestinal F. nucleatum.


Assuntos
Neoplasias Colorretais , Infecções por Fusobacterium , Neoplasias Hepáticas , Masculino , Animais , Camundongos , Fusobacterium nucleatum/genética , Neoplasias Colorretais/genética , Metronidazol/farmacologia , Metronidazol/uso terapêutico , Antígeno Ki-67 , Camundongos Nus , RNA Ribossômico 16S , Infecções por Fusobacterium/complicações , Infecções por Fusobacterium/tratamento farmacológico , Infecções por Fusobacterium/genética , DNA
6.
BMJ Case Rep ; 16(4)2023 Apr 21.
Artigo em Inglês | MEDLINE | ID: mdl-37085282

RESUMO

We present here the challenging case of severe Lemierre syndrome in a healthy woman in her late twenties, whose clinical presentation was characterised by lung abscesses and disseminated systemic abscesses in the brain, the abdomen and the soft-tissues, as a likely consequence of a patent foramen ovale. Blood cultures were positive for Fusobacterium necrophorum and a right lingual vein thrombosis was detected at a late stage when the patient developed a septic shock. Initial antimicrobial therapy with metronidazole and ceftriaxone was modified to meropenem due to progressive worsening. The patient underwent laparoscopy and neurosurgical drainage of a cerebral abscess. She spent many days in the intensive care unit and recovered fully after 6 weeks on meropenem therapy. Although considered rare, the incidence of Lemierre syndrome, a potentially life-threatening condition, is increasing. The clinician should promptly recognise and treat it while being aware of its potential atypical presentations.


Assuntos
Abscesso Encefálico , Infecções por Fusobacterium , Síndrome de Lemierre , Feminino , Humanos , Síndrome de Lemierre/diagnóstico , Síndrome de Lemierre/tratamento farmacológico , Síndrome de Lemierre/microbiologia , Meropeném/uso terapêutico , Abscesso Encefálico/diagnóstico por imagem , Abscesso Encefálico/tratamento farmacológico , Ceftriaxona/uso terapêutico , Metronidazol/uso terapêutico , Fusobacterium necrophorum , Antibacterianos/uso terapêutico , Infecções por Fusobacterium/complicações , Infecções por Fusobacterium/diagnóstico , Infecções por Fusobacterium/tratamento farmacológico
7.
Anaerobe ; 76: 102587, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35595214

RESUMO

OBJECTIVES: Otomastoiditis caused by the anaerobic Fusobacterium necrophorum (F. necrophorum) often induces severe complications, such as meningitis and sinus thrombosis. Early diagnosis is difficult, partly because little is known about specific early signs. Comprehensive research about clinically chosen antimicrobial therapy has not been done yet and prognostic information about otomastoiditis caused by F. necrophorum is scarce. More knowledge about this subject is required. METHODS: In this retrospective cohort study, we included all cases of otomastoiditis caused by F. necrophorum treated in two university medical centres in the Netherlands during the past 10 years. Data was gathered from patient records and analysed using independent sample T-tests and Chi2-tests. RESULTS: This study reveals that otomastoiditis caused by F. necrophorum potentially induces neurological sequelae. Thereby, 80% of all included patients (n = 16) needed readmission within six months due to recurrence or complications of otomastoiditis caused by F. necrophorum. Mean (range) of age, CRP and temperature were 4.5 years (0.9-29.3), 243 mg/L (113-423) and 40 °C (37-41). All patients were hospitalized and treated with antibiotics, mostly metronidazole (n = 13/16) and a ß -lactam (n = 15/16). Additional treatment contained low molecular weight heparin (83%, n = 10/12), dexamethasone (78%, n = 7/9) and/or surgery (80%, n = 12/16, whereof 9/12 mastoidectomy). CONCLUSIONS: Patients and/or their parents need to be informed about this potential unfortunate prognosis when otomastoiditis caused by F. necrophorum is diagnosed. To improve early diagnosis, otomastoiditis caused by F. necrophorum should be suspected and therefore immediately cultured when a) young children present with otomastoiditis, with b) high CRP values, and/or c) vomiting and decreased consciousness.


Assuntos
Infecções por Fusobacterium , Fusobacterium necrophorum , Antibacterianos/uso terapêutico , Criança , Pré-Escolar , Estudos de Coortes , Infecções por Fusobacterium/complicações , Infecções por Fusobacterium/diagnóstico , Infecções por Fusobacterium/tratamento farmacológico , Humanos , Prognóstico , Estudos Retrospectivos
8.
BMC Infect Dis ; 22(1): 309, 2022 Mar 29.
Artigo em Inglês | MEDLINE | ID: mdl-35351006

RESUMO

BACKGROUND: Fusobacterium nucleatum (F. nucleatum) is a resident anaerobic bacterium, which in rare cases may invade blood from the head and neck or the digestive tract to cause bacteremia and induce venous thrombosis. F. nucleatum is closely related to abdominal tumors, but it has not been reported in relation to renal tumors. We report herein a possible case. CASE PRESENTATION: This patient had kidney cancer with thrombosis in the right renal vein but had no sign of infection. After radical nephrectomy, thrombi formed in his left renal vein, and when removed, severe sepsis occurred. He did not respond to treatment with antibiotics and died, but the blood culture done confirmed that he had F. nucleatum bacteremia. CONCLUSION: F. nucleatum may also be associated with kidney cancer, and could cause post-operative renal vein thrombosis, and sepsis or septic shock after thrombectomy.


Assuntos
Infecções por Fusobacterium , Sepse , Composição de Bases , Infecções por Fusobacterium/diagnóstico , Infecções por Fusobacterium/tratamento farmacológico , Fusobacterium nucleatum , Humanos , Masculino , Nefrectomia , Filogenia , RNA Ribossômico 16S , Sepse/complicações , Análise de Sequência de DNA
9.
Ann Lab Med ; 42(2): 188-195, 2022 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-34635612

RESUMO

Background: Fusobacterium species are obligately anaerobic, gram-negative bacilli. Especially, F. nucleatum and F. necrophorum are highly relevant human pathogens. We investigated clinical differences in patients infected with Fusobacterium spp. and determined the antimicrobial susceptibility of Fusobacterium isolates. Methods: We collected clinical data of 86 patients from whom Fusobacterium spp. were isolated from clinical specimens at a tertiary-care hospital in Korea between 2003 and 2020. In total, 76 non-duplicated Fusobacterium isolates were selected for antimicrobial susceptibility testing by the agar dilution method, according to the Clinical and Laboratory Standards Institute guidelines (M11-A9). Results: F. nucleatum was most frequently isolated from blood cultures and was associated with hematologic malignancy, whereas F. necrophorum was mostly prevalent in head and neck infections. Anti-anaerobic agents were more commonly used to treat F. nucleatum and F. varium infections than to treat F. necrophorum infections. We observed no significant difference in mortality between patients infected with these species. All F. nucleatum and F. necrophorum isolates were susceptible to the antimicrobial agents tested. F. varium was resistant to clindamycin (48%) and moxifloxacin (24%), and F. mortiferum was resistant to penicillin G (22%) and ceftriaxone (67%). ß-Lactamase activity was not detected. Conclusions: Despite the clinical differences among patients with clinically important Fusobacterium infections, there was no significant difference in the mortality rates. Some Fusobacterium spp. were resistant to penicillin G, ceftriaxone, clindamycin, or moxifloxacin. This study may provide clinically relevant data for implementing empirical treatment against Fusobacterium infections.


Assuntos
Anti-Infecciosos , Infecções por Fusobacterium , Fusobacterium , Infecções por Fusobacterium/diagnóstico , Infecções por Fusobacterium/tratamento farmacológico , Humanos , República da Coreia , Centros de Atenção Terciária
10.
Sci Rep ; 11(1): 23719, 2021 12 09.
Artigo em Inglês | MEDLINE | ID: mdl-34887459

RESUMO

Fusobacterium nucleatum is associated with the progression of colorectal cancer. Thus, the possibility of preventing colorectal cancer or its progression by targeting F. nucleatum has been explored. As F. nucleatum is associated with periodontitis, we analysed whether treating periodontitis could influence F. nucleatum abundance in the colon. Patients with colorectal tumours who underwent colonoscopy were recruited. Patients diagnosed with periodontitis by a dentist were treated for approximately 3 months. Endoscopic resection of colorectal tumours was performed after periodontitis treatment, and resected tumours were pathologically classified as high-(HGD) or low-grade dysplasia (LGD). Saliva and stool samples were collected before and after the treatment. Of the 58 patients with colorectal tumours, 31 were included in the study, 16 showed improvement in periodontitis, and 11 showed no improvement. Stool F. nucleatum levels before treatment were significantly lower in the LGD group than in the HGD group. A significant decrease in faecal F. nucleatum levels was observed in patients who underwent successful treatment but not in those whose treatment failed. Salivary F. nucleatum levels were not altered in patients despite periodontal treatment. Thus, successful periodontitis treatment reduces stool F. nucleatum levels and may aid research on periodontitis and suppression of colorectal cancer development.


Assuntos
Neoplasias Colorretais/complicações , Infecções por Fusobacterium/tratamento farmacológico , Infecções por Fusobacterium/etiologia , Fusobacterium nucleatum , Periodontite/tratamento farmacológico , Periodontite/etiologia , Idoso , Antibacterianos/uso terapêutico , Carga Bacteriana , Comorbidade , Gerenciamento Clínico , Suscetibilidade a Doenças , Fezes/microbiologia , Feminino , Microbioma Gastrointestinal/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Saliva/microbiologia , Resultado do Tratamento
11.
BMC Cancer ; 21(1): 1212, 2021 Nov 13.
Artigo em Inglês | MEDLINE | ID: mdl-34774023

RESUMO

There is a growing level of interest in the potential role inflammation has on the initiation and progression of malignancy. Notable examples include Helicobacter pylori-mediated inflammation in gastric cancer and more recently Fusobacterium nucleatum-mediated inflammation in colorectal cancer. Fusobacterium nucleatum is a Gram-negative anaerobic bacterium that was first isolated from the oral cavity and identified as a periodontal pathogen. Biofilms on oral squamous cell carcinomas are enriched with anaerobic periodontal pathogens, including F. nucleatum, which has prompted hypotheses that this bacterium could contribute to oral cancer development. Recent studies have demonstrated that F. nucleatum can promote cancer by several mechanisms; activation of cell proliferation, promotion of cellular invasion, induction of chronic inflammation and immune evasion. This review provides an update on the association between F. nucleatum and oral carcinogenesis, and provides insights into the possible mechanisms underlying it.


Assuntos
Infecções por Fusobacterium/complicações , Fusobacterium nucleatum , Neoplasias Bucais/microbiologia , Carcinoma de Células Escamosas de Cabeça e Pescoço/microbiologia , Animais , Antibacterianos/uso terapêutico , Aderência Bacteriana , Biofilmes , Movimento Celular , Proliferação de Células , Neoplasias Colorretais/microbiologia , Infecções por Fusobacterium/tratamento farmacológico , Fusobacterium nucleatum/imunologia , Fusobacterium nucleatum/fisiologia , Humanos , Evasão da Resposta Imune , Imunidade Celular , Inflamação/microbiologia , Metronidazol/uso terapêutico , Camundongos , Neoplasias Bucais/tratamento farmacológico , Invasividade Neoplásica , Porphyromonas gingivalis , Carcinoma de Células Escamosas de Cabeça e Pescoço/tratamento farmacológico
12.
Anaerobe ; 71: 102420, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-34314865

RESUMO

A 42-year-old man was referred to the Department of Orthopedic Surgery with pain over his right greater trochanter and signs of systemic infection. CT showed an enhanced mass in his gluteus maximus as well as gas in the biceps femoris over the underlying hip joint. Tissue biopsy yielded Fusobacterium nucleatum and Actinomyces turicensis. The patient was successfully treated for 6 weeks with amoxicillin/clavulanic acid 875mg/125mg and metronidazole 500mg.


Assuntos
Actinomycetaceae/isolamento & purificação , Infecções por Actinomycetales/microbiologia , Bacteriemia/microbiologia , COVID-19/imunologia , Infecções por Fusobacterium/microbiologia , Fusobacterium nucleatum/isolamento & purificação , Quadril/microbiologia , Abscesso/tratamento farmacológico , Abscesso/microbiologia , Actinomycetaceae/efeitos dos fármacos , Actinomycetaceae/genética , Infecções por Actinomycetales/tratamento farmacológico , Adulto , Antibacterianos/uso terapêutico , COVID-19/virologia , Infecções por Fusobacterium/tratamento farmacológico , Fusobacterium nucleatum/efeitos dos fármacos , Fusobacterium nucleatum/genética , Humanos , Hospedeiro Imunocomprometido , Masculino , SARS-CoV-2/genética , SARS-CoV-2/isolamento & purificação
13.
Andes Pediatr ; 92(1): 93-98, 2021 Feb.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-34106188

RESUMO

INTRODUCTION: Fusobacterium nucleatum is an anaerobic bacillus that is part of the oral microbiota and dental pla que. This can cause local and potentially remote infections, which are exceptional in pediatrics. Ob jective: To present the case of a patient with lung injury with chest wall invasion by Fusobacterium nucleatum. CLINICAL CASE: An 11-year-old female immunocompetent patient who consulted due to a two-week history of cough, night sweats, without fever or weight loss, and increased volume at the left spleen thoracic level. There was no history of chest wall trauma or travel outside the country. Two weeks before the onset of symptoms, she was treated for dental caries. Imaging studies and CT scan showed left spleen pneumonia, which invades the pleura and the chest wall. A minimal thoracotomy was performed, releasing a thick, foul-smelling liquid. The studies for common germs and tubercu losis were negative. Hematology ruled out tumor lesions. The anaerobic study reported the develo pment of Fusobacterium nucleatum. The patient was treated with penicillin followed by amoxicillin presenting good clinical and radiological responses. The dental procedure was suspected as the cause of infection. CONCLUSIONS: Fusobacterium nucleatum can occasionally cause remote or extra-oral in fections in immunocompetent patients, such as pneumonia with chest wall invasion, therefore it is necessary to bear it in mind.


Assuntos
Infecções por Fusobacterium , Fusobacterium nucleatum/isolamento & purificação , Pneumonia Bacteriana/microbiologia , Amoxicilina/uso terapêutico , Antibacterianos/uso terapêutico , Criança , Cárie Dentária/complicações , Cárie Dentária/terapia , Feminino , Infecções por Fusobacterium/diagnóstico por imagem , Infecções por Fusobacterium/tratamento farmacológico , Infecções por Fusobacterium/cirurgia , Humanos , Penicilinas/uso terapêutico , Pneumonia Bacteriana/diagnóstico por imagem , Pneumonia Bacteriana/tratamento farmacológico , Pneumonia Bacteriana/cirurgia , Parede Torácica/microbiologia , Toracotomia
14.
J Pediatric Infect Dis Soc ; 10(8): 886-888, 2021 Sep 23.
Artigo em Inglês | MEDLINE | ID: mdl-34038561

RESUMO

Although Fusobacterium necrophorum is well described as an emerging pathogen of acute mastoiditis in young children, infection with other anaerobes can lead to similar severe sequelae including intracranial and extracranial suppurative thrombophlebitis and sepsis. We describe a patient whose unremarkable exposure history assumed increased significance upon obtaining the results of 16S next generation sequencing from a surgical specimen. The novel pathogen Bacteroides pyogenes is reviewed herein.


Assuntos
Infecções por Fusobacterium , Síndrome de Lemierre , Tromboflebite , Bacteroides/genética , Criança , Pré-Escolar , Infecções por Fusobacterium/diagnóstico , Infecções por Fusobacterium/tratamento farmacológico , Fusobacterium necrophorum , Humanos , Síndrome de Lemierre/diagnóstico , Síndrome de Lemierre/tratamento farmacológico
15.
BMJ Case Rep ; 14(3)2021 Mar 18.
Artigo em Inglês | MEDLINE | ID: mdl-33737279

RESUMO

Fusobacterium nucleatum is part of the commensal flora of the oral cavity, frequently associated with periodontal infections. We describe the case of a 49-year-old woman, on immunsuppressive therapy for multiple sclerosis, who presented with a 3-month history of debilitating back pain. She had a recent episode of periodontitis, and was under regular dental review. Her MRI scan demonstrated findings suggestive of L2-L3 spondylodiscitis. Her CT-guided biopsy yielded negative cultures and the patient failed two courses of empirical antibiotic treatment. With clinical and radiological disease progression, she underwent a percutaneous disc washout and biopsy, which subsequently grew F. nucleatum Treatment with clindamycin and metronidazole was commenced orally for 6 weeks. She improved gradually, and at 1 year follow-up was asymptomatic. The diagnosis of spondylodiscitis caused by F. nucleatum is challenging. The perseverance on identification by surgical biopsy, minimally invasive washout and targeted antibiotics are the mainstay of effective treatment.


Assuntos
Discite , Infecções por Fusobacterium , Esclerose Múltipla , Periodontite , Discite/diagnóstico , Discite/tratamento farmacológico , Feminino , Infecções por Fusobacterium/complicações , Infecções por Fusobacterium/diagnóstico , Infecções por Fusobacterium/tratamento farmacológico , Fusobacterium nucleatum , Humanos , Pessoa de Meia-Idade
16.
BMJ Case Rep ; 14(1)2021 Jan 26.
Artigo em Inglês | MEDLINE | ID: mdl-33500312

RESUMO

Fusobacterium nucleatum is a periodontal commensal and pathogen. In rare cases, these anaerobic gram-negative bacilli have been reported to cause pyogenic liver abscesses (PLAs). We describe a patient who developed a periodontal abscess during the COVID-19 pandemic and was unable to access the restricted General Dental Services at this time. She subsequently developed a F. nucleatum bacteraemia and liver abscess. The non-specific signs and symptoms experienced meant the patient self-isolated due to suspected COVID-19 infection and presentation to hospital was delayed. We also include the results of a literature search of other cases of PLAs attributed to F. nucleatum PLAs often develop insidiously. They require percutaneous drainage and prolonged antimicrobial therapy. Clinicians should be aware of this rare complication of a dentoalveolar infection in a patient who is systemically unwell.


Assuntos
Infecções por Fusobacterium/diagnóstico , Abscesso Hepático Piogênico/microbiologia , Abscesso Periodontal/microbiologia , Antibacterianos/uso terapêutico , Bacteriemia/diagnóstico , COVID-19/epidemiologia , Drenagem , Feminino , Infecções por Fusobacterium/diagnóstico por imagem , Infecções por Fusobacterium/tratamento farmacológico , Humanos , Abscesso Hepático Piogênico/diagnóstico por imagem , Abscesso Hepático Piogênico/tratamento farmacológico , Pessoa de Meia-Idade , Pandemias , Quarentena , SARS-CoV-2 , Tempo para o Tratamento , Tomografia Computadorizada por Raios X
17.
Trends Cancer ; 7(3): 185-187, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33309240

RESUMO

Fusobacterium nucleatum is an oral bacterium associated with colorectal cancer (CRC) proliferation, chemoresistance, inflammation, metastasis, and now DNA damage. While controlling F. nucleatum through antibiotics could reduce cancer severity, this article proposes additional strategies to block Fusobacterium-host interactions, as well as treatment of activated host immune and oncogenic signaling pathways in CRC.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Colorretais/tratamento farmacológico , Infecções por Fusobacterium/tratamento farmacológico , Fusobacterium nucleatum/efeitos dos fármacos , Interações Hospedeiro-Patógeno/efeitos dos fármacos , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêutico , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Proteínas de Bactérias/antagonistas & inibidores , Proteínas de Bactérias/metabolismo , Carcinogênese/genética , Carcinogênese/imunologia , Neoplasias Colorretais/genética , Neoplasias Colorretais/imunologia , Neoplasias Colorretais/microbiologia , Dano ao DNA/efeitos dos fármacos , Infecções por Fusobacterium/genética , Infecções por Fusobacterium/imunologia , Infecções por Fusobacterium/microbiologia , Fusobacterium nucleatum/patogenicidade , Interações Hospedeiro-Patógeno/genética , Interações Hospedeiro-Patógeno/imunologia , Humanos , Mucosa Bucal/microbiologia , Microambiente Tumoral/efeitos dos fármacos , Microambiente Tumoral/genética , Microambiente Tumoral/imunologia
18.
Orthop Surg ; 12(6): 2026-2030, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33150710

RESUMO

OBJECTIVE: Fusobacterium nucleatum is an anaerobic gram-negative bacilli that is one of the oral and other mucosal surface microbiota. It involves a wide range of human diseases and was first found in periodontal diseases, but reports of bone-related infections caused by F. nucleatum are rare, especially periprosthetic joint infections (PJI). METHODS: Here, we present the first case of acute hematogenous PJI of the hip joint caused by F. nucleatum, and debridement, antibiotics, and implant retention (DAIR) was performed. RESULTS: The patient was successfully treated with DAIR, identification of isolates by metagenomics next-generation sequencing was confirmed by polymerase chain reaction. CONCLUSIONS: For stable acute hematogenous PJI after hip replacement, quick and accurate diagnosis, the identification of pathogenic microorganisms, and the use of DAIR combined with sufficient sensitive antibiotics have a certain clinical effect and can achieve the purpose of both preserving the prosthesis and infection control.


Assuntos
Antibacterianos/uso terapêutico , Artroplastia de Quadril , Desbridamento , Infecções por Fusobacterium/tratamento farmacológico , Infecções Relacionadas à Prótese/tratamento farmacológico , Infecções Relacionadas à Prótese/microbiologia , Infecções Relacionadas à Prótese/cirurgia , Idoso , Feminino , Fusobacterium nucleatum , Prótese de Quadril , Humanos , Odontalgia/cirurgia
19.
Anaerobe ; 61: 102099, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31513845

RESUMO

Fusobacterium nucleatum is a common oral commensal bacterium capable of severe invasive infections. We report a case of a diffuse bilateral pneumopathy with F. nucleatum-positive blood culture successfully treated by common antibiotics in a patient receiving eculizumab for a drug-induced thrombotic microangiopathy (TMA). It is the first described case of a severe F. nucleatum-associated infection in a patient undergoing terminal complement inhibitor therapy. We suggest providing preventive dental care before eculizumab initiation.


Assuntos
Anticorpos Monoclonais Humanizados/efeitos adversos , Bacteriemia/etiologia , Infecções por Fusobacterium/diagnóstico , Infecções por Fusobacterium/etiologia , Fusobacterium nucleatum , Pneumonia Bacteriana/diagnóstico , Pneumonia Bacteriana/etiologia , Idoso , Anticorpos Monoclonais Humanizados/uso terapêutico , Neoplasias do Ânus/complicações , Neoplasias do Ânus/tratamento farmacológico , Inativadores do Complemento/efeitos adversos , Inativadores do Complemento/uso terapêutico , Feminino , Infecções por Fusobacterium/tratamento farmacológico , Fusobacterium nucleatum/genética , Humanos , Pneumonia Bacteriana/tratamento farmacológico , Tomografia Computadorizada por Raios X , Ultrassonografia Doppler
20.
J Bronchology Interv Pulmonol ; 26(2): 132-136, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30908392

RESUMO

Chronic pleural infection is characterized by thickened pleura and nonexpandable lung often requiring definitive surgical intervention, such as decortication and/or pleural obliteration procedures. Such procedures are associated with significant morbidity and require proper patient selection for a successful outcome. We report a cohort of 11 patients with pleural space infection and a nonexpandable lung treated with tunneled pleural catheters (TPCs). Following placement, hospital discharge and TPC removal occurred after a median of 5 and 36 days, respectively. Three patients presented with residual loculated effusion that resolved with instillation of intrapleural fibrinolytic therapy. One patient eventually required open window thoracostomy for ongoing pleural infection due to poor medical compliance with TPC care and drainage instructions. TPCs represent an alternative option for drainage of an infected pleural space in nonsurgical candidates with a nonexpandable lung. Their use, as a compliment to traditional treatment, may facilitate prompt hospital discharge and ambulatory management in patients with limited life expectancy.


Assuntos
Catéteres , Infecções/cirurgia , Pleurisia/cirurgia , Toracostomia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Candidíase/tratamento farmacológico , Candidíase/cirurgia , Tubos Torácicos , Drenagem , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/cirurgia , Feminino , Fluoroscopia , Infecções por Fusobacterium/tratamento farmacológico , Infecções por Fusobacterium/cirurgia , Humanos , Infecções/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Pleurisia/tratamento farmacológico , Estudos Retrospectivos , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/cirurgia , Infecções Estreptocócicas/tratamento farmacológico , Infecções Estreptocócicas/cirurgia , Cirurgia Torácica Vídeoassistida , Toracoscopia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA